Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LM103 in advanced solid tumors
NCT05366478Phase 1Recruiting
- Sponsor
- Suzhou BlueHorse Therapeutics
- Start
- May 2022
- Primary completion
- May 2024
- Modality
- Tumor-Infiltrating Lymphocytes (TILs)
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of LM103 in solid tumor, sponsored by Suzhou BlueHorse Therapeutics. Primary endpoint: Incidence and severity of adverse events (AEs) at 1 year. Started May 2022; status: recruiting.
02
Drugs
LM103
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05366478.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05366478.